NASDAQ:SRNE - Sorrento Therapeutics Stock Price, Forecast & News

Sorrento Therapeutics trades on the NASDAQ under the ticker symbol "SRNE."

Sorrento Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, March 20th 2020. View Earnings Estimates for Sorrento Therapeutics.

3 analysts have issued 1 year price objectives for Sorrento Therapeutics' shares. Their forecasts range from $12.00 to $30.00. On average, they anticipate Sorrento Therapeutics' stock price to reach $21.00 in the next year. This suggests a possible upside of 496.6% from the stock's current price. View Analyst Price Targets for Sorrento Therapeutics.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sorrento Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sorrento Therapeutics.

Media headlines about SRNE stock have trended very positive this week, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Sorrento Therapeutics earned a daily sentiment score of 4.0 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Sorrento Therapeutics.

Some companies that are related to Sorrento Therapeutics include National Research (NRC), Intrexon (XON), STARPHARMA HOLD/S (SPHRY), Auxly Cannabis Group (CBWTF), Luna Innovations (LUNA), Eloxx Pharmaceuticals (ELOX), Pieris Pharmaceuticals (PIRS), Anavex Life Sciences (AVXL), Bioanalytical Systems (BASI), BIOQUAL (BIOQ), HedgePath Pharmaceuticals (HPPI), Cleveland BioLabs (CBLI), Tenax Therapeutics (TENX), Vitality Biopharma (VBIO) and US Stem Cell (USRM).

Based on aggregate information from My MarketBeat watchlists, some companies that other Sorrento Therapeutics investors own include Novavax (NVAX), Synergy Pharmaceuticals (SGYP), Alibaba Group (BABA), Cara Therapeutics (CARA), Micron Technology (MU), NVIDIA (NVDA), Exelixis (EXEL), Canopy Growth (CGC), Amarin (AMRN) and Gilead Sciences (GILD).

Sorrento Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include California State Teachers Retirement System (0.15%), Barclays PLC (0.07%), California Public Employees Retirement System (0.05%), Millennium Management LLC (0.03%), Metropolitan Life Insurance Co NY (0.01%) and Commonwealth Equity Services LLC (0.01%). Company insiders that own Sorrento Therapeutics stock include Abg Management Ltd, George K Ng and Pacific Medtech (Bvi) Ltd Asia. View Institutional Ownership Trends for Sorrento Therapeutics.

SRNE stock was sold by a variety of institutional investors in the last quarter, including Metropolitan Life Insurance Co NY. View Insider Buying and Selling for Sorrento Therapeutics.

SRNE stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, California Public Employees Retirement System, Barclays PLC, California State Teachers Retirement System, Tower Research Capital LLC TRC , SG Americas Securities LLC and Commonwealth Equity Services LLC. View Insider Buying and Selling for Sorrento Therapeutics.

Shares of SRNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of SRNE stock can currently be purchased for approximately $3.52.

Sorrento Therapeutics has a market capitalization of $579.15 million and generates $21.19 million in revenue each year. The biopharmaceutical company earns $-203,540,000.00 in net income (profit) each year or ($1.92) on an earnings per share basis. Sorrento Therapeutics employs 382 workers across the globe.View Additional Information About Sorrento Therapeutics.

The official website for Sorrento Therapeutics is http://www.sorrentotherapeutics.com/.

Sorrento Therapeutics' mailing address is 4955 DIRECTORS PLACE, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-203-4100 or via email at [email protected]